Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium
Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting
Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…Abstract Number: 1805 • 2019 ACR/ARP Annual Meeting
Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study
Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…Abstract Number: 2095 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients
Background/Purpose: The ACR and CDC recommend influenza (“flu”) and 23-valent pneumococcal polysaccharide (PPSV23) vaccination for inflammatory arthritis (IA) patients on immunosuppression. This study aimed to:…Abstract Number: 2103 • 2019 ACR/ARP Annual Meeting
Anti-TNF Therapy in Patients with HIV Infection
Background/Purpose: Patients with Human Immunodeficiency Virus (HIV) infection may benefit from the use of anti-Tumor Necrosis Factor (TNF) therapy in the setting of inflammatory disease,…Abstract Number: 2107 • 2019 ACR/ARP Annual Meeting
Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database
Background/Purpose: Pneumonia is a common cause of death not only in the general population but also in patients with rheumatoid arthritis (RA). In particular, patients…Abstract Number: 2109 • 2019 ACR/ARP Annual Meeting
Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study
Background/Purpose: Tuberculosis (TB) infection is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, especially in developing countries. Previous studies have…Abstract Number: 2122 • 2019 ACR/ARP Annual Meeting
Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions
Background/Purpose: Septic arthritis is known to cause significant morbidity due to joint destruction and mortality if timely and adequate treatment is not given. In this study,…Abstract Number: 2125 • 2019 ACR/ARP Annual Meeting
Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up
Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…Abstract Number: 2521 • 2019 ACR/ARP Annual Meeting
Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Background/Purpose: Mortality in Systemic Lupus Erythematosus (SLE) is increased compared to the general population. We sought to investigate mortality rates and associated factors in a…Abstract Number: 2583 • 2019 ACR/ARP Annual Meeting
Prevalence and Risk Factors of Herpes Zoster Reactivation in Patients with Biopsy Proven Lupus Nephritis Undergoing Immunosuppressive Therapies
Background/Purpose: To study the prevalence of Herpes Zoster (HZ) reactivation in patients with biopsy confirmed lupus nephritis (LN) undergoing immunosuppressive therapies.Methods: Patients who had biopsy…Abstract Number: 2826 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study
Background/Purpose: It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk…Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting
Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 32
- Next Page »